


Accepted Manuscript

Selection of P2Y12 inhibitor in percutaneous coronary intervention and/or acute coronary syndrome

Udaya Tantry, Eliano P. Navarese, Aung Myat, Paul Gurbel



PII: S0033-0620(18)30020-3
DOI: <https://doi.org/10.1016/j.pcad.2018.01.003>
Reference: YPCAD 860

To appear in:

Received date: 10 January 2018
Accepted date: 10 January 2018

Please cite this article as: Udaya Tantry, Eliano P. Navarese, Aung Myat, Paul Gurbel , Selection of P2Y12 inhibitor in percutaneous coronary intervention and/or acute coronary syndrome. The address for the corresponding author was captured as affiliation for all authors. Please check if appropriate. Ypcad(2018), <https://doi.org/10.1016/j.pcad.2018.01.003>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Selection of P2Y₁₂ Inhibitor in Percutaneous Coronary Intervention and/or Acute Coronary Syndrome

Udaya Tantry¹, Eliano P Navarese¹, Aung Myat², Paul Gurbel¹

¹ Inova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Falls Church, VA, USA

² Sussex Cardiac Centre, Brighton and Sussex University Hospitals NHS Trust and Faculty of Medicine, Brighton and Sussex Medical School, Brighton, UK.

Short Title: Selecting P2Y₁₂ Inhibitors

Conflict of Interest/Disclosures: None

Dr. Gurbel reports grants from Amgen, Haemonetics, DCRI, Medicure, Merck, NIH, Janssen, Idorsia, Ionis, and Bayer; personal fees from Boehringer, Merck, Janssen, Bayer, Medicure, and UptoDate and has a patent Platelet function testing issued.

Other authors report no disclosures

Send Correspondence to:

Paul A. Gurbel MD, FACC

Director, Interventional Cardiology and Cardiovascular Medicine Research

Inova Center for Thrombosis Research and Drug Development

Inova Heart and Vascular Institute

3300 Gallows Road

Falls Church, VA 22042

Fax: 410-367-2590: Phone: 410-367-2596

E-mail: Paul.Gurbel@inova.org

Key Words

acute coronary syndrome, antiplatelet therapy, coronary artery disease, clopidogrel, cangrelor, myocardial infarction, percutaneous coronary intervention, platelets, P2Y₁₂ inhibitor, prasugrel, ticagrelor.

Download English Version:

<https://daneshyari.com/en/article/8675247>

Download Persian Version:

<https://daneshyari.com/article/8675247>

[Daneshyari.com](https://daneshyari.com)